American Journal of Obstetrics & Gynecology
Volume 198, Issue 1 , Pages 28.e1-28.e5 , January 2008

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

  • Manfredi Rizzo, MD, PhD

      Affiliations

    • Department of Clinical Medicine and Emerging Diseases, University of Palermo, Palermo, Italy
    • Corresponding Author InformationReprints: Manfredi Rizzo, MD, PhD, Dipartimento di Medicina Clinica e delle Patologie Emergenti, Universita’ di Palermo, Via del Vespro, 141, 90127 Palermo, Italy.
    • ,
  • Kaspar Berneis, MD

      Affiliations

    • Division of Endocrinology and Diabetology, University Hospital, Zurich, Switzerland.
    • ,
  • Enrico Carmina, MD

      Affiliations

    • Department of Clinical Medicine and Emerging Diseases, University of Palermo, Palermo, Italy
    • ,
  • Giovam Battista Rini, MD

      Affiliations

    • Department of Clinical Medicine and Emerging Diseases, University of Palermo, Palermo, Italy

Received 7 May 2007 ,Revised 3 September 2007 ,Accepted 8 September 2007.

References 

  1. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998;339:861–867
  2. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000;132:989–993
  3. Guzick DS. Cardiovascular risk in PCOS. J Clin Endocrinol Metab. 2004;89:3694–3695
  4. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000;20:2414–2421
  5. Christian RC, Dumesic DA, Behrenbeck T, Oberg A, Sheedy PF, Fitzpatrick L. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2562–2568
  6. Cussons AJ, Stuckey BGA, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis. 2006;185:227–239
  7. Berneis K, Rizzo M, Fruzzetti F, Lazzaroni V, Carmina E. Atherogenic lipoprotein phenotype and LDL size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:186–189
  8. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report). Circulation. 2002;106:3143–3421
  9. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  10. Dejager S, Pichard C, Giral P, et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf). 2001;54:455–462
  11. Legro RS, Blanche P, Krauss RM, Lobo RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril. 1999;72:990–995
  12. Lemieux S, Lewis GF, Ben-Chetrit A, Steiner G, Greenblatt EM. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. J Clin Endocrinol Metab. 1999;84:4278–4282
  13. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf). 2001;54:447–453
  14. Rizzo M, Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovasc Drug Ther. 2006;20:205–217
  15. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139–146
  16. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002;87:569–574
  17. Ng EHY, Wat NMS, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod. 2001;16:1625–1631
  18. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003;327:951–953
  19. Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol. 2005;153:115–121
  20. Lv L, Liu Y. Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance. J Huazhong Univ Sci Technolog Med Sci. 2004;24:480–482
  21. Kilicdag EB, Bagis T, Zeyneloglu HB, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod. 2005;20:894–899
  22. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod. 2003;18:1618–1625
  23. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death. N Engl J Med. 2007;356:2457–2471
  24. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association?. Endocr Rev. 2003;24:302–312
  25. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90:2545–2549

 Cite this article as: Rizzo M, Berneis K, Carmina E, et al. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Am J Obstet Gynecol 2008;198:28.e1-28.e5.

PII: S0002-9378(07)01113-1

doi: 10.1016/j.ajog.2007.09.014

American Journal of Obstetrics & Gynecology
Volume 198, Issue 1 , Pages 28.e1-28.e5 , January 2008

Article Tools

* Image Usage & Resolution